Chardan Capital began coverage on shares of Vicore Pharma (NASDAQ:VCRE – Free Report) in a research note issued to investors on Wednesday,Benzinga reports. The brokerage issued a buy rating and a $15.00 price objective on the stock.
VCRE has been the subject of a number of other reports. Jefferies Financial Group began coverage on shares of Vicore Pharma in a report on Friday, October 9th. They set a “buy” rating and a $25.00 price objective for the company. Weiss Ratings began coverage on shares of Vicore Pharma in a report on Thursday, October 8th. They issued a “sell (e-)” rating on the stock. Finally, Wall Street Zen raised shares of Vicore Pharma to a “hold” rating in a research report on Saturday, October 24th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $20.00.
Check Out Our Latest Analysis on Vicore Pharma
Vicore Pharma Trading Up 3.1%
NASDAQ:VCRE traded up $0.32 on Wednesday, hitting $10.32. The stock had a trading volume of 12,244 shares, compared to its average volume of 26,775. Vicore Pharma has a 52 week low of $7.88 and a 52 week high of $17.80.
Vicore Pharma (NASDAQ:VCRE – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($0.04) EPS for the quarter. The firm had revenue of $0.06 million during the quarter.
About Vicore Pharma
Vicore Pharma is a Swedish clinical-stage biopharmaceutical company focused on developing treatments for severe respiratory diseases, particularly pulmonary fibrosis and other conditions involving lung injury and impaired tissue repair. The company is headquartered in Gothenburg, Sweden, and conducts research and clinical development activities aimed at addressing significant unmet medical needs.
Vicore’s lead drug candidate is buloxibutid, also known as C21, an oral small-molecule agonist of the angiotensin II type 2 receptor.
Recommended Stories
- Five stocks we like better than Vicore Pharma
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
Receive News & Ratings for Vicore Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicore Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
